Phacoemulsifi cation surgery was performed without complication and the best corrected visual acuity of the left eye improved to 20/20 after surgery.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:We aim to present a case who developed mature cataracts shortly after the use of tamoxifen, a selective estrogen receptor modulator, for male infertility.
📊
Key Findings & Data:A 38-year-old male presented with painless, rapidly progressive decreased visual acuity in the left eye for two months.
💡
Conclusion & Impact:Phacoemulsifi cation surgery was performed without complication and the best corrected visual acuity of the left eye improved to 20/20 after surgery.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
We aim to present a case who developed mature cataracts shortly after the use of tamoxifen, a selective estrogen receptor modulator, for male infertility. A 38-year-old male presented with painless, rapidly progressive decreased visual acuity in the left eye for two months. He was taking 20 mg of tamoxifen daily for 3 months. Anterior segment examination of the left eye proved a milky-white cataract. Patient had no family history or other secondary causes of cataract such as previous ocular trauma, ocular disease or systemic disease. Phacoemulsifi cation surgery was performed without complication and the best corrected visual acuity of the left eye improved to 20/20 after surgery.
🔖
Cite This Article
UZUN, F., OKUTUCU, M., UZUN, H. (2020). Mature Cataracts in a Young Patient Under Tamoxifen Treatment for Male Infertility: A Case Report. Glokom Katarakt, Cilt: 15 - Sayı: 1, 55–57. https://ajindex.com/articles/226805
References (16)
K aiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep. 1978;62:315-20
Noureddin BN, Seoud M, Bashshur Z, et al. Ocular toxicity in low-dose tamoxifen: a prospective study. Eye (Lond).1999;13(Pt 6):729-33
Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer. 1992;15;69:2961-4
Zhang JJ, Jacob TJ, Hardy SP, et al. Lens opacifi cation by antioestrogens: tamoxifen vs ICI 182,780. Br J Pharmacol. 1995;115:1347-8
Zhang JJ, Jacob TJ, Valverde MA, et al. Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J Clin Invest. 1994;94:1690-7
Paganini-Hill A, Clark LJ. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;60:167-72
Gorin MB, Day R, Costantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol. 1998;125:493-501
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-88
Bradbury BD, Lash TL, Kaye JA, et al. Tamoxifen and cataracts: a null association. Breast Cancer Res Treat. 2004;87:189-96
Parkkari M, Paakkala AM, Salminen L, et al. Finnish Breast Cancer Group. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized followup study. Acta Ophthalmol Scand. 2003;81:495-9
Wibowo E, Pollock PA, Hollis N, et al. Tamoxifen in men: a review of adverse events. Andrology. 2016;4:776-88
Pemmaraju N, Munsell MF, Hortobagyi GN, et al. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects. Ann Oncol. 2012;23:1471-4
Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol. 2010;17:17-21
Bradley KL, Tyldesley S, Speers CH, et al. Contemporary systemic therapy for male breast cancer. Clin Breast Cancer. 2014;14:31-9
Tsai DC, Chen SJ, Chiou SH, et al. Should we discontinue tamoxifen in a patient with vision-threatening ocular toxicity related to low-dose tamoxifen therapy? Eye (Lond.). 2003;17:276-8.1. K aiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep. 1978;62:315-20